Search research articles
Contact Us
Filters
Showing results (141-150 of 627) with videos related to
Page
of 63
Sort By:
JACC. Heart Failure
|
November 3, 2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
JingWei Li, Mark Woodward, Vlado Perkovic, et al.
International Journal of Cardiology
|
September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials
Jie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
ESC Heart Failure
|
November 21, 2019
Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure
Abhinav Sharma, Jingjing Wu, Justin A Ezekowitz, et al.
Diabetologia
|
August 11, 2019
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Zien Zhou, Meg Jardine, Vlado Perkovic, et al.
Circulation. Cardiovascular Interventions
|
August 17, 2019
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention
Christoph B Olivier, Jun Fan, Mariam Askari, et al.
American Heart Journal
|
September 25, 2004
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome
Hassan Kassem-Moussa, Kenneth W Mahaffey, Carmelo Graffagnino, et al.
Journal of the American Society of Hypertension : JASH
|
November 14, 2015
Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction
Tatiana Kuznetsova, Francois Haddad, Judita Knez, et al.
Diabetes Care
|
January 22, 2024
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials
Sheldon W Tobe, Thomas A Mavrakanas, Harpreet S Bajaj, et al.
Journal of Thrombosis and Thrombolysis
|
November 19, 2010
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome
Richard C Becker, Kenneth W Mahaffey, Hongqiu Yang, et al.
Circulation
|
February 2, 2000
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
D B Mark, R A Harrington, A M Lincoff, et al.
Page
of 63
Search research articles
Search
Showing results (141-150 of 627) with videos related to
Sort By:
Page
of 63
JACC. Heart Failure
|
November 3, 2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
JingWei Li, Mark Woodward, Vlado Perkovic, et al.
International Journal of Cardiology
|
September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials
Jie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
ESC Heart Failure
|
November 21, 2019
Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure
Abhinav Sharma, Jingjing Wu, Justin A Ezekowitz, et al.
Diabetologia
|
August 11, 2019
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Zien Zhou, Meg Jardine, Vlado Perkovic, et al.
Circulation. Cardiovascular Interventions
|
August 17, 2019
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention
Christoph B Olivier, Jun Fan, Mariam Askari, et al.
American Heart Journal
|
September 25, 2004
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome
Hassan Kassem-Moussa, Kenneth W Mahaffey, Carmelo Graffagnino, et al.
Journal of the American Society of Hypertension : JASH
|
November 14, 2015
Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction
Tatiana Kuznetsova, Francois Haddad, Judita Knez, et al.
Diabetes Care
|
January 22, 2024
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials
Sheldon W Tobe, Thomas A Mavrakanas, Harpreet S Bajaj, et al.
Journal of Thrombosis and Thrombolysis
|
November 19, 2010
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome
Richard C Becker, Kenneth W Mahaffey, Hongqiu Yang, et al.
Circulation
|
February 2, 2000
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
D B Mark, R A Harrington, A M Lincoff, et al.
Page
of 63